• Recruiting

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

Updated: Oct 3

CARTITUDE-2

Ciltacabtagene Autoleuce

CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.


Sponsor

Janssen Research & Development, LLC


Legend Biotech

 

ClinicalTrials.gov Identifier: NCT04133636

Official Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

First Posted : October 21, 2019

Click here for ClinicalTrials.gov

 

CART - BCMA : National Cancer Institute

JNJ-68284528 - ciltacabtagene autoleucel

 

EHA2022 Oral Presentation

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA

CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY


Click here for details

 

COMY 22 - Session 15: Abstract communications

CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B

Click here for details

 

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Abstract 8013

2021 ASCO Annual Meeting

Click here for details

 

3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster III

Hematology Disease Topics & Pathways:

Biological, Clinical Trials, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinical Research, Diseases, Therapies, Infusion, Lymphoid Malignancies

Monday, December 13, 2021, 6:00 PM-8:00 PM


Learn more

 

2910 CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Program: Oral and Poster Abstracts

Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster II

Hematology Disease Topics & Pathways:

Biological, Clinical Trials, Plasma Cell Disorders, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Infusion, Lymphoid Malignancies

Sunday, December 12, 2021, 6:00 PM-8:00 PM


Learn more

 

RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.


Data from the CARTITUDE program at ASH 2021 will provide data on the earlier use of cilta-cel, with updated results from Cohort A of the Phase 2 CARTITUDE-2 study, which included patients who were refractory to lenalidomide with progressive multiple myeloma after 1-3 lines of therapy (Abstract #3866) and the first data from Cohort B of the Phase 2 CARTITUDE-2 study which enrolled patients following early relapse after initial therapy that included proteasome inhibitors and immunomodulatory drugs (Abstract #2910). Both sets of results will be featured in poster presentations.


https://www.jnj.com/janssen-to-present-the-strength-and-promise-of-its-hematologic-malignancies-portfolio-and-pipeline-at-ash-2021

 

OAB-043-Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B


OAB-044 Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting antibody-drug conjugate treatment -Adam Cohen


OAB-045 Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A -Adam Cohen


OAB-062 Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment -Jesús San-Miguel



#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California

IMS 2022 Abstract EBook

https://www.myelomasociety.org/


#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California (themyelomaclinicaltrials.com)


 

* Ciltacabtagene Autoleuce


- California: University of California San Francisco

- Georgia: Emory University Atlanta

- Illinois: Northwestern University Chicago

- Illinois: University of Chicago

- Indiana: Indiana University Indianapolis

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Minnesota: Mayo Clinic Rochester Minnesota

- Missouri: Washington University School of Medicine Saint Louis

- New Jersey: Hackensack University Medical Center

- New Jersey: Rutgers Cancer Institute of New Jersey New Brunswick

- New York: Roswell Park Cancer Institute Buffalo

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- North Carolina: Levine Cancer Institute Charlotte

- Pennsylvania: University of Pennsylvania Philadelphia

- Pennsylvania: University of Pittsburgh Medical Center

- Texas: Baylor University Medical Center Dallas

- Texas: The University of Texas MD Anderson Cancer Center Houston

- Washington: Fred Hutchinson Cancer Center Seattle

 

Locations

United States, California

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Maryland

United States, Massachusetts

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Texas

United States, Washington

Europe

France

Germany

Netherlands

Spain

Belgium

Asia

Israel

Saudi Arabia

Singapore

 

RELATED POSTS


NCT03548207: CARTITUDE-1 - Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in RRMM

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04181827: CARTITUDE 4 - Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relapsed len ref RRMM

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Click here for details


NCT04923893: CARTITUDE-5 - Phase 3 - VRd f/by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned)

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Click here for details


NCT05257083: CARTITUDE-6 - Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT NDMM

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Click here for details








Posts Archive